1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs" is currently closed and not accepting applications.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). These programs are congressionally mandated set-aside programs for U.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) | National Institute of General Medical Sciences NIH has congressionally mandated set-aside programs for U.S. small businesses to engage in research and development activities that have strong potential for commercialization. Awards are intended to: Stimulate technological innovation. Use small business to meet federal research and development needs.
Increase private sector commercialization of innovations derived from federal research and development. The NIH SBIR/STTR program consists of two phases: Phase 1 (R41/R43) establishes the scientific and technical merit and feasibility as well as the potential for commercialization of the proposed Phase 2 (R42/R44) continues research or research and development (R&D) efforts initiated in Phase 1.
NIH SBIR/STTR grant solicitation announcements and additional information are website. You can also find information on the difference between SBIR and STTR application requirements . NIGMS-Specific SBIR Guidance The goal of NIGMS is to support innovative SBIR projects that could benefit the research communities related to its mission.
SBIR/STTR grant applications are accepted in most of the scientific areas for which the Institute provides support. Specific topics of research interest to NIGMS [PDF] . The NIGMS SBIR program like the vast majority of NIGMS-funded research is investigator-initiated.
Applicants propose what to do, how to do it, and the best path toward commercialization. NIGMS will not accept applications with budget requests exceeding the statutory budget limitations defined in the specific SBIR/STTR notice of considered to fit one or more of the SBA-approved topics for awards over the statutory budget limitations listed in SBA-Approved Waiver Topics of the SBIR/STTR Program Descriptions and Topics .
Applicants who are considering a project with a budget exceeding the hard budget cap defined in the notice of funding opportunity should contact the NIGMS SBIR coordinator early in the process of application preparation and at least six weeks prior to the anticipated submission due date. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
NIGMS support of Phase 2B competing renewal grant applications is limited and should be discussed in advance with the NIGMS SBIR coordinator. NIGMS does participate in the Commercialization Readiness Pilot (CRP) program designed to facilitate the transition of previously funded SBIR and STTR Phase 2 and Phase 2B projects to the commercialization stage by providing additional support for technical assistance.
List of NIGMS funding announcements (program announcements, requests for applications and notices) for the SBIR For information about NIGMS SBIR/STTR grants administration and management, NIGMS_GAB_SBIR@nigms. nih. gov .
NIH Research Evaluation and Commercialization Hub (REACH) The NIH Research Evaluation and Commercialization Hub (REACH) program was established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs.
Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH’s mission. For more information REACH and current For information about NIGMS SBIR programs, email Eddie Billingslea, Ph. D.
This page last updated on
According to the current listing, eligibility includes: For-profit U. S. small businesses with 500 employees or fewer. Principal Investigator must have primary employment with the small business for SBIR. Confirm the full requirements in the official notice before applying.
The current listing shows varies (Phase 1 typically up to $314,363; Phase 2 up to $2,095,748, with potential enhancements up to $650,000). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was May 13, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is funded by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NIH Small Business Innovation Research (SBIR) Program (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-24-245) / (Parent SBIR [R43/R44] Clinical Trial Required) (PA-24-246) is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). NIGMS participates in the NIH SBIR program, which supports small businesses engaging in research and development activities with strong potential for commercialization.
PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS). This omnibus solicitation supports small businesses engaged in research and development with strong commercialization potential, addressing challenges faced by NIH populations experiencing health disparities. This includes technology and service innovations.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article